Coherus Biosciences | CHRS - Current Liabilities


Coherus Biosciences reported $140.39M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Fujifilm JPY 1.26T 57.74B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026
Zoetis USD 2.05B 182M Mar/2026